Literature DB >> 10098739

In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data.

B Stausbøl-Grøn1, S M Bentzen, K E Jørgensen, O S Nielsen, T Bundgaard, J Overgaard.   

Abstract

The aim was to characterize the variation in the cellular in vitro radiosensitivities in squamous cell carcinomas of the head and neck, and to test for a possible correlation between different measures of radiosensitivity and the clinical and histopathological data. Cellular in vitro radiosensitivities were assessed in tumour biopsies from 71 patients using the modified Courtenay-Mills soft agar clonogenic assay combined with an immunocytochemical analysis. Radiosensitivity was quantified as the surviving fraction after a radiation dose of 2 Gy irrespective of cell type (overall SF2), or based on identification of cell type (tumour cell SF2, fibroblast SF2). Sixty-three biopsies were from primary tumours, and eight were from recurrences. Overall plating efficiency ranged from 0.005 to 1.60% with a median of 0.052%. The majority of the colonies obtained from the biopsies were fibroblast marker-positive; the proportion of tumour marker-positive colonies ranged from 1 to 88% with a median of 15%. The median overall SF2 was 0.47 (range 0.24-0.96), the median tumour cell SF2 was 0.50 (range 0.11-1.0) and the median fibroblast SF2 was 0.49 (range 0.24-1.0). Comparing data from independent experiments, the overall SF2 was significantly correlated with the SF2 of fibroblasts (2P = 0.006) but not with the tumour cell SF2. The tumour cell and fibroblast radiosensitivities measured in the same individuals were not correlated (r= 0.06, 95% CI [-0.19, 0.30]):This finding seems to preclude a strong correlation between the radiosensitivity of tumour cells and fibroblasts. Concerning the clinical characteristics, neither of the measures of tumour radiosensitivity was correlated with T- and N-category, stage, tumour size, sex and age. However, the tumour cell radiosensitivity decreased with increasing grade of histopathological differentiation (2P = 0.012). The same tendency was found in two independent analyses of the same patient material. This correlation was not significant in case of the overall SF2 or the fibroblast SF2.

Entities:  

Mesh:

Year:  1999        PMID: 10098739      PMCID: PMC2362224          DOI: 10.1038/sj.bjc.6690172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Evaluation of surviving fraction at 2 Gy as a potential prognostic factor for the radiotherapy of carcinoma of the cervix.

Authors:  C M West; S E Davidson; R D Hunter
Journal:  Int J Radiat Biol       Date:  1989-11       Impact factor: 2.694

2.  Radiosensitivity of human head and neck squamous cell carcinomas in primary culture and its potential as a predictive assay of tumor radiocurability.

Authors:  W A Brock; F L Baker; L J Peters
Journal:  Int J Radiat Biol       Date:  1989-11       Impact factor: 2.694

3.  The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors.

Authors:  N Azumi; H Battifora
Journal:  Am J Clin Pathol       Date:  1987-09       Impact factor: 2.493

4.  A radiobiological comparison of human tumor soft-agar clonogenic assays.

Authors:  C M West; R M Sutherland
Journal:  Int J Cancer       Date:  1986-06-15       Impact factor: 7.396

Review 5.  Predictive assays of tumor radiocurability.

Authors:  L J Peters; W A Brock; J D Chapman; G Wilson
Journal:  Am J Clin Oncol       Date:  1988-06       Impact factor: 2.339

6.  Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-05       Impact factor: 7.038

7.  Radiosensitivity testing of primary cervical carcinoma: evaluation of intra- and inter-tumour heterogeneity.

Authors:  S E Davidson; C M West; S A Roberts; J H Hendry; R D Hunter
Journal:  Radiother Oncol       Date:  1990-08       Impact factor: 6.280

8.  Evidence for individual differences in the radiosensitivity of human skin.

Authors:  S L Tucker; I Turesson; H D Thames
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

9.  Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-09       Impact factor: 7.038

10.  Cellular radiosensitivity of primary head and neck squamous cell carcinomas and local tumor control.

Authors:  W A Brock; F L Baker; J L Wike; S L Sivon; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-06       Impact factor: 7.038

View more
  4 in total

1.  Molecular biology: the key to personalised treatment in radiation oncology?

Authors:  D G Hirst; T Robson
Journal:  Br J Radiol       Date:  2010-09       Impact factor: 3.039

Review 2.  Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas.

Authors:  Joanna Kałafut; Arkadiusz Czerwonka; Alinda Anameriç; Alicja Przybyszewska-Podstawka; Julia O Misiorek; Adolfo Rivero-Müller; Matthias Nees
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

Review 3.  Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Authors:  Amy J C Dohmen; Justin E Swartz; Michiel W M Van Den Brekel; Stefan M Willems; René Spijker; Jacques Neefjes; Charlotte L Zuur
Journal:  Cancers (Basel)       Date:  2015-08-28       Impact factor: 6.639

4.  Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy: comparison of two fractionation schemes.

Authors:  Kailash Chandra Pandey; Swaroop Revannasiddaiah; Nirdosh Kumar Pant; Vipul Nautiyal; Madhup Rastogi; Manoj Kumar Gupta
Journal:  Indian J Palliat Care       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.